查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
人类免疫缺乏病毒治疗药的全球市场:成长，未来展望，竞争分析 (2025年～2033年)
市场调查报告书
商品编码
1645228

人类免疫缺乏病毒治疗药的全球市场:成长，未来展望，竞争分析 (2025年～2033年)

Human Immunodeficiency Virus Therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2025 - 2033
出版日期: | 出版商: Acute Market Reports | 英文 178 Pages | 商品交期: 最快1-2个工作天内

价格

人类免疫缺乏病毒 (HIV) 药物市场是製药业的一个部门，专注于研究、开发和分销针对 HIV（一种导致获得性免疫缺陷症候群 (AIDS) 的病毒）的药物和治疗。自 20 世纪 80 年代发现以来，爱滋病毒/爱滋病已成为重大公共卫生威胁，导致全球数百万人死亡。对有效治疗的持续需求，加上医学研究的进步，推动该市场走向传染病治疗的前沿。预计 2025 年至 2033 年期间人类免疫缺陷病毒治疗市场复合年增长率为 1.3%。

推动因素：全球爱滋病毒/爱滋病发病率和盛行率不断上升

毫无疑问，爱滋病毒治疗市场成长的主要动力是全球爱滋病毒/爱滋病感染者数量的持续增加。根据联合国爱滋病规划署（UNAIDS）的数据，2019 年全球约有 3,800 万人感染爱滋病毒。这一数字凸显了有效治疗的迫切性和需求。此外，某些地区，特别是撒哈拉以南非洲地区受到的影响尤其严重，全球必须加强对抗病毒的传播和影响。作为应对，许多政府和国际组织加强了资金和措施的投入，进一步刺激了研究和治疗的需求。

机会：新型治疗方法的出现

新疗法的开发为持续对抗爱滋病毒/爱滋病带来了重大机会。近年来，人们对基因疗法和 CRISPR 技术作为 HIV 的潜在治疗或治癒方法的兴趣日益浓厚。最近发表在科学期刊上的研究表明，这些方法有可能瞄准并消灭体内的爱滋病毒储存库。这些进步标誌着从传统抗逆转录病毒疗法向更明确、更具潜在治癒力的疗法的范式转变，为市场扩张带来了巨大的机会。

阻碍因素：治疗费用高昂和可近性问题

儘管取得了进展，但爱滋病毒药物市场仍面临着一个阻碍因素：高昂的治疗费用往往限制了药物的可及性，尤其是在中低收入国家。抗病毒疗法虽然有效，但价格昂贵，发展中地区的卫生系统难以普遍提供这种疗法。世界卫生组织（WHO）多次强调这种差距，指出虽然在改善治疗机会方面取得了进展，但仍存在巨大差距，主要是由于晚期爱滋病毒药物成本过高。

课题：治疗依从性与抗药性

爱滋病毒治疗的主要课题之一是治疗依从性和相关的抗药性风险。爱滋病毒治疗需要严格遵守用药方案，任何疏忽都可能导致病毒对药物产生抗药性。这种抗药性不仅威胁患者的健康，也导致抗药性病毒的传播，使治疗方案变得复杂。美国疾病管制与预防中心（CDC）指出，抗药性问题已成为亟待解决的问题，并列举了由于不坚持治疗而导致的爱滋病毒抗药性问题的出现​​和传播的例子。

依药物类型分析

就药品类型而言，市场分为品牌药和仿製药。到 2024 年，品牌药销售额将超过仿製药销售额。在製药巨头的大量研发投入、专利保护和广泛行销活动的支持下，这些品牌药物在市场上占据了重要的地位。特别是在专利法严格执行的地区，它是可靠性、有效性和创新的代名词。然而，仿製药预计将在 2025 年至 2033 年期间实现最高的复合年增长率。随着几种品牌爱滋病毒药物的专利到期，仿製药预计将变得更加普遍。这些仿製药具有成本效益和高效性，并有望填补治疗方面的空白，特别是在中低收入国家，因此成为成长最快的领域。

依药物类别分析

根据药物类别，HIV 治疗方案由核苷类似物逆转录酶抑制剂 (NRTIs)、非核苷逆转录酶抑制剂 (NNRTIs)、进入/融合抑制剂、蛋白酶抑制剂 (PIs)、整合酶抑制剂和辅助受体拮抗剂组成。由于 NRTI 在市场上的长期存在及其在 HAART（高效抗逆转录病毒疗法）中的基础性作用，预计 2024 年 NRTI 将在销售方面处于领先地位。几十年来它一直是爱滋病治疗的基石。然而，从 2025 年到 2033 年，整合酶抑制剂的主导地位预计将脱颖而出，预计将呈现最高的复合年增长率。转向这些抑制剂与其效力、减少的副作用和快速降低病毒量的有效性有关，这已在多项临床试验中得到证实。

区域分析

从地理位置来看，由于强大的医疗基础设施、较高的认知度以及在研发方面的大量投资，预计北美将在 2024 年占据爱滋病治疗药物市场最大的收入占有率。然而，2025 年至 2033 年的十年间，爱滋病毒感染率的重点可能会放在非洲，预计那里的复合年增长率最高。预计这一增长将受到国际合作、医疗保健和基础设施投资以及对可获得且负担得起的爱滋病毒治疗的迫切需求的推动。

竞争趋势

在竞争格局方面，2025 年将由 AbbVie Inc.、Boehringer Ingelheim International Inc.、Bristol-Myers Squibb Company、Cipla、Genentech, Inc.、Gilead Sciences, Inc.、Merck & Co., Inc. 和 ViiV Medical Inc. 等领先公司占据主导地位。这些公司拥有强大的药品管道、策略联盟、病患权益保护计画和显着的市场主导地位。这些公司的策略通常包括积极研发、申请专利以及与当地公司合作以使药品更为广泛地普及。随着我们迈向 2025 年及 2033 年，市场竞争格局预计将变得更加多样化。随着仿製药的进入和本土製造商的崛起，尤其是在高需求领域，协作、创新和适应性已成为行业参与者的指导原则。

目录

第1章 序文

  • 分析内容
    • 分析的目的
    • 对象者
    • 主要的提供内容
  • 市场区隔
  • 分析方法
    • 阶段Ⅰ:二次调查
    • 阶段Ⅱ:一次调查
    • 阶段Ⅲ:有学识者检讨
    • 前提条件
    • 所采用的方法

第2章 摘要整理

第3章 人类免疫缺乏病毒治疗药市场:竞争分析

  • 主要供应商的市场定位
  • 供应商所采用的策略
  • 主要的产业策略

第4章 人类免疫缺乏病毒治疗药市场:常量分析和市场动态

  • 简介
  • 全球人类免疫缺乏病毒治疗药市场 (以金额为准，2023～2033年)
  • 市场动态
    • 推动市场要素
    • 阻碍市场要素
    • 主要课题
    • 主要的机会
  • 促进因素与阻碍因素的影响分析
  • Seesaw分析
  • 波特的五力分析
    • 供应商电力
    • 买主电力
    • 替代品的威胁
    • 新加入厂商业者的威胁
    • 竞争企业间的敌对关係
  • PESTEL分析
    • 政治形势
    • 经济形势
    • 技术性形势
    • 法律上的形势
    • 社会形势

第5章 人类免疫缺乏病毒治疗药市场:药物类别 (2023～2033年)

  • 市场概要
  • 成长·收益分析:2024年 vs 2033年
  • 市场区隔
    • 品牌医药品
    • 学名药

第6章 人类免疫缺乏病毒治疗药市场:各类药物 (2023～2033年)

  • 市场概要
  • 成长·收益分析:2024年 vs 2033年
  • 市场区隔
    • 核苷类似物逆转录酶抑制剂 (NRTI)
    • 非核苷逆转录酶抑制剂（NNRTI）
    • 进入和融合抑制剂
    • 蛋白酶抑​​製剂（PI）
    • 整合酶抑制剂
    • 辅助受体拮抗剂

第7章 北美的人类免疫缺乏病毒治疗药市场 (2023～2033年)

  • 市场概要
  • 人类免疫缺乏病毒治疗药市场:药物类别 (2023～2033年)
  • 人类免疫缺乏病毒治疗药市场:各类药物 (2023～2033年)
  • 人类免疫缺乏病毒治疗药市场:各地区 (2023～2033年)
    • 北美
      • 美国
      • 加拿大
      • 其他北美地区

第8章 英国·EU各国的人类免疫缺乏病毒治疗药市场 (2023～2033年)

  • 市场概要
  • 人类免疫缺乏病毒治疗药市场:药物类别 (2023～2033年)
  • 人类免疫缺乏病毒治疗药市场:各类药物 (2023～2033年)
  • 人类免疫缺乏病毒治疗药市场:各地区 (2023～2033年)
    • 英国·EU各国
      • 英国
      • 德国
      • 西班牙
      • 义大利
      • 法国
      • 其他欧洲地区

第9章 亚太地区的人类免疫缺乏病毒治疗药市场 (2023～2033年)

  • 市场概要
  • 人类免疫缺乏病毒治疗药市场:药物类别 (2023～2033年)
  • 人类免疫缺乏病毒治疗药市场:各类药物 (2023～2033年)
  • 人类免疫缺乏病毒治疗药市场:各地区 (2023～2033年)
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳洲
      • 韩国
      • 其他亚太地区

第10章 南美的人类免疫缺乏病毒治疗药市场 (2023～2033年)

  • 市场概要
  • 人类免疫缺乏病毒治疗药市场:药物类别 (2023～2033年)
  • 人类免疫缺乏病毒治疗药市场:各类药物 (2023～2033年)
  • 人类免疫缺乏病毒治疗药市场:各地区 (2023～2033年)
    • 南美
      • 巴西
      • 墨西哥
      • 其他南美国家地区

第11章 中东·非洲的人类免疫缺乏病毒治疗药市场 (2023～2033年)

  • 市场概要
  • 人类免疫缺乏病毒治疗药市场:药物类别 (2023～2033年)
  • 人类免疫缺乏病毒治疗药市场:各类药物 (2023～2033年)
  • 人类免疫缺乏病毒治疗药市场:各地区 (2023～2033年)
    • 中东·非洲
      • GCC
      • 非洲
      • 其他中东·非洲地区

第12章 企业简介

  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Genentech Inc.
  • Gilead Sciences Inc.
  • Merck & Co. Inc.
  • ViiV Healthcare
  • 其他
Product Code: 120-12-24

The human immunodeficiency virus (HIV) therapeutics market pertains to the sector of the pharmaceutical industry that focuses on the research, development, and distribution of treatments and drugs for HIV, the virus that leads to Acquired Immunodeficiency Syndrome (AIDS). Since its discovery in the 1980s, HIV/AIDS has posed a significant public health threat, resulting in millions of deaths worldwide. The consistent demand for effective treatments, combined with advancements in medical research, has propelled this market to the forefront of infectious disease therapeutics. human immunodeficiency virus therapeutics market is estimated to grow at a CAGR of 1.3% from 2025 to 2033.

Driver: Increased Global Incidence and Prevalence of HIV/AIDS

The undeniable, primary driver for the growth of the HIV therapeutics market has been the continual rise in the number of HIV/AIDS cases worldwide. According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), around 38 million people were living with HIV globally in 2019. The sheer magnitude of this number underscores the urgency and demand for effective treatments. Additionally, certain regions, particularly Sub-Saharan Africa, have been disproportionately affected, intensifying the global efforts to combat the spread and repercussions of the virus. In response, numerous governments and international organizations have ramped up funding and initiatives, further driving the demand for research and therapeutics.

Opportunity: Emergence of Novel Therapeutic Approaches

As the fight against HIV/AIDS continues, one significant opportunity has been the development of novel therapeutic modalities. In recent years, there has been a growing interest in gene therapies and CRISPR technology as potential treatments or even cures for HIV. Recent studies, published in scientific journals, have illustrated the potential of these approaches to target and eradicate HIV reservoirs in the body. These advancements suggest a paradigm shift from traditional antiretroviral therapies to more definitive and potentially curative approaches, representing a significant opportunity for market expansion.

Restraint: High Treatment Costs and Accessibility Issues

Despite advancements, the HIV therapeutics market faces the restraint of high treatment costs, which often limits accessibility, especially in low- and middle-income countries. Antiretroviral treatments, while effective, can be expensive, making it challenging for healthcare systems in developing regions to provide them universally. The World Health Organization (WHO) has frequently highlighted this disparity, noting that while progress has been made in increasing access to treatment, significant gaps remain, primarily due to the prohibitive costs associated with advanced HIV drugs.

Challenge: Treatment Adherence and Drug Resistance

One of the critical challenges in HIV treatment is the issue of treatment adherence and the consequent risk of drug resistance. HIV treatment requires strict adherence to drug regimens, and any lapses can lead to the virus developing resistance to the medication. This resistance not only jeopardizes the patient's health but can also lead to the spread of drug-resistant strains of the virus, complicating treatment protocols. The Centers for Disease Control and Prevention (CDC) has flagged drug resistance as a pressing concern, citing instances where individuals, due to inconsistent treatment adherence, have developed and transmitted drug-resistant HIV strains.

Drug Type Insights

By drug type, the market can be dissected into branded drugs and generic drugs. In 2024, branded drugs overshadowed their generic counterparts in terms of revenue generation. These branded drugs, backed by heavy R&D investments, patent protections, and extensive marketing campaigns by pharmaceutical giants, carved a significant niche in the market. They were synonymous with trust, efficacy, and innovation, especially in regions with robust patent law enforcement. Nevertheless, from 2025 to 2033, generic drugs are projected to register the highest CAGR. As patents of several branded HIV drugs expire, the market is anticipated to witness a proliferation of generic versions. These generic drugs, cost-effective yet efficacious, promise to bridge the treatment accessibility gap, especially in low and middle-income countries, making them the fastest-growing segment.

Drug Class Insights

Transitioning to drug class segmentation, the HIV therapeutics landscape is a mosaic of Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Entry and Fusion Inhibitors, Protease Inhibitors (PIs), Integrase Inhibitors, and Coreceptor Antagonists. NRTIs, owing to their longer presence in the market and foundational role in Highly Active Antiretroviral Therapy (HAART), reigned supreme in revenue generation in 2024. They've been the cornerstone of HIV treatment for decades. Yet, the span from 2025 to 2033 is expected to underscore the prominence of Integrase Inhibitors, which are predicted to manifest the highest CAGR. The shift towards these inhibitors can be linked to their potency, reduced side effects, and efficacy in reducing viral loads rapidly, as documented in various clinical trials.

Regional Insights

On a geographical plane, the HIV therapeutics market in 2024 saw North America capturing the largest revenue share, driven by robust healthcare infrastructure, high awareness levels, and substantial investments in R&D. However, the decade from 2025 to 2033 is likely to spotlight the African region, which, despite its high HIV prevalence, is forecasted to experience the highest CAGR. The growth is expected to be fueled by international collaborations, investments in healthcare infrastructure, and a pressing demand for accessible and affordable HIV treatments.

Competitive Trends

In the competitive arena, 2025 had stalwarts like AbbVie Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Cipla Inc., Genentech, Inc., Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare dominating the scene. These companies, with their robust drug pipelines, strategic alliances, and patient assistance programs, had a significant hold on the market. Their strategies often encompassed aggressive R&D, patent acquisitions, and forging partnerships with local entities for broader drug accessibility. As the market treads into 2025 and beyond to 2033, a more diversified competitive landscape is anticipated. With the entry of generic drugs and the rise of local manufacturers, especially in high-demand regions, collaboration, innovation, and adaptability are set to be the guiding tenets for industry players.

Historical & Forecast Period

This study report represents an analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. The key data points that enable the estimation of Human Immunodeficiency Virus Therapeutics market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users & consumption volume, price, and value.

Geographical revenues generated by countries considered in the report

Micro and macro environment factors that are currently influencing the Human Immunodeficiency Virus Therapeutics market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top-down and bottom-up approach for validation of market estimation assures logical, methodical, and mathematical consistency of the quantitative data.

  • Market Segmentation
  • Drug Type
    • Branded Drugs
    • Generic Drugs
  • Drug Class
    • Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Entry and Fusion Inhibitors
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Coreceptor Antagonists
  • Region Segment (2023-2033; US$ Million)
  • North America
  • U.S.
  • Canada
  • Rest of North America
  • UK and European Union
  • UK
  • Germany
  • Spain
  • Italy
  • France
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East and Africa
  • GCC
  • Africa
  • Rest of Middle East and Africa

Key questions answered in this report

  • What are the key micro and macro environmental factors that are impacting the growth of Human Immunodeficiency Virus Therapeutics market?
  • What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2033.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Human Immunodeficiency Virus Therapeutics market?
  • Which is the largest regional market for Human Immunodeficiency Virus Therapeutics market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Human Immunodeficiency Virus Therapeutics market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Human Immunodeficiency Virus Therapeutics market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Human Immunodeficiency Virus Therapeutics Market
  • 2.2. Global Human Immunodeficiency Virus Therapeutics Market, By Drug Type, 2024 (US$ Million)
  • 2.3. Global Human Immunodeficiency Virus Therapeutics Market, By Drug Class, 2024 (US$ Million)
  • 2.4. Global Human Immunodeficiency Virus Therapeutics Market, By Geography, 2024 (US$ Million)
  • 2.5. Attractive Investment Proposition by Geography, 2024

3. Human Immunodeficiency Virus Therapeutics Market: Competitive Analysis

  • 3.1. Market Positioning of Key Human Immunodeficiency Virus Therapeutics Market Vendors
  • 3.2. Strategies Adopted by Human Immunodeficiency Virus Therapeutics Market Vendors
  • 3.3. Key Industry Strategies

4. Human Immunodeficiency Virus Therapeutics Market: Macro Analysis & Market Dynamics

  • 4.1. Introduction
  • 4.2. Global Human Immunodeficiency Virus Therapeutics Market Value, 2023 - 2033, (US$ Million)
  • 4.3. Market Dynamics
    • 4.3.1. Market Drivers
    • 4.3.2. Market Restraints
    • 4.3.3. Key Challenges
    • 4.3.4. Key Opportunities
  • 4.4. Impact Analysis of Drivers and Restraints
  • 4.5. See-Saw Analysis
  • 4.6. Porter's Five Force Model
    • 4.6.1. Supplier Power
    • 4.6.2. Buyer Power
    • 4.6.3. Threat Of Substitutes
    • 4.6.4. Threat Of New Entrants
    • 4.6.5. Competitive Rivalry
  • 4.7. PESTEL Analysis
    • 4.7.1. Political Landscape
    • 4.7.2. Economic Landscape
    • 4.7.3. Technology Landscape
    • 4.7.4. Legal Landscape
    • 4.7.5. Social Landscape

5. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 5.3. Market Segmentation
    • 5.3.1. Branded Drugs
    • 5.3.2. Generic Drugs

6. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)

  • 6.1. Market Overview
  • 6.2. Growth & Revenue Analysis: 2024 Versus 2033
  • 6.3. Market Segmentation
    • 6.3.1. Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
    • 6.3.2. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • 6.3.3. Entry and Fusion Inhibitors
    • 6.3.4. Protease Inhibitors (PIs)
    • 6.3.5. Integrase Inhibitors
    • 6.3.6. Coreceptor Antagonists

7. North America Human Immunodeficiency Virus Therapeutics Market, 2023-2033, USD (Million)

  • 7.1. Market Overview
  • 7.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
  • 7.3. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
  • 7.4.Human Immunodeficiency Virus Therapeutics Market: By Region, 2023-2033, USD (Million)
    • 7.4.1.North America
      • 7.4.1.1. U.S.
        • 7.4.1.1.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 7.4.1.1.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 7.4.1.2. Canada
        • 7.4.1.2.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 7.4.1.2.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 7.4.1.3. Rest of North America
        • 7.4.1.3.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 7.4.1.3.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)

8. UK and European Union Human Immunodeficiency Virus Therapeutics Market, 2023-2033, USD (Million)

  • 8.1. Market Overview
  • 8.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
  • 8.3. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
  • 8.4.Human Immunodeficiency Virus Therapeutics Market: By Region, 2023-2033, USD (Million)
    • 8.4.1.UK and European Union
      • 8.4.1.1. UK
        • 8.4.1.1.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 8.4.1.1.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 8.4.1.2. Germany
        • 8.4.1.2.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 8.4.1.2.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 8.4.1.3. Spain
        • 8.4.1.3.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 8.4.1.3.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 8.4.1.4. Italy
        • 8.4.1.4.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 8.4.1.4.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 8.4.1.5. France
        • 8.4.1.5.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 8.4.1.5.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 8.4.1.6. Rest of Europe
        • 8.4.1.6.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 8.4.1.6.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)

9. Asia Pacific Human Immunodeficiency Virus Therapeutics Market, 2023-2033, USD (Million)

  • 9.1. Market Overview
  • 9.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
  • 9.3. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
  • 9.4.Human Immunodeficiency Virus Therapeutics Market: By Region, 2023-2033, USD (Million)
    • 9.4.1.Asia Pacific
      • 9.4.1.1. China
        • 9.4.1.1.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 9.4.1.1.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 9.4.1.2. Japan
        • 9.4.1.2.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 9.4.1.2.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 9.4.1.3. India
        • 9.4.1.3.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 9.4.1.3.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 9.4.1.4. Australia
        • 9.4.1.4.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 9.4.1.4.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 9.4.1.5. South Korea
        • 9.4.1.5.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 9.4.1.5.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 9.4.1.6. Rest of Asia Pacific
        • 9.4.1.6.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 9.4.1.6.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)

10. Latin America Human Immunodeficiency Virus Therapeutics Market, 2023-2033, USD (Million)

  • 10.1. Market Overview
  • 10.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
  • 10.3. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
  • 10.4.Human Immunodeficiency Virus Therapeutics Market: By Region, 2023-2033, USD (Million)
    • 10.4.1.Latin America
      • 10.4.1.1. Brazil
        • 10.4.1.1.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 10.4.1.1.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 10.4.1.2. Mexico
        • 10.4.1.2.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 10.4.1.2.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 10.4.1.3. Rest of Latin America
        • 10.4.1.3.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 10.4.1.3.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)

11. Middle East and Africa Human Immunodeficiency Virus Therapeutics Market, 2023-2033, USD (Million)

  • 11.1. Market Overview
  • 11.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
  • 11.3. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
  • 11.4.Human Immunodeficiency Virus Therapeutics Market: By Region, 2023-2033, USD (Million)
    • 11.4.1.Middle East and Africa
      • 11.4.1.1. GCC
        • 11.4.1.1.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 11.4.1.1.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 11.4.1.2. Africa
        • 11.4.1.2.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 11.4.1.2.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)
      • 11.4.1.3. Rest of Middle East and Africa
        • 11.4.1.3.1. Human Immunodeficiency Virus Therapeutics Market: By Drug Type, 2023-2033, USD (Million)
        • 11.4.1.3.2. Human Immunodeficiency Virus Therapeutics Market: By Drug Class, 2023-2033, USD (Million)

12. Company Profile

  • 12.1. AbbVie Inc.
    • 12.1.1. Company Overview
    • 12.1.2. Financial Performance
    • 12.1.3. Product Portfolio
    • 12.1.4. Strategic Initiatives
  • 12.2. Boehringer Ingelheim International GmbH
    • 12.2.1. Company Overview
    • 12.2.2. Financial Performance
    • 12.2.3. Product Portfolio
    • 12.2.4. Strategic Initiatives
  • 12.3. Bristol-Myers Squibb Company
    • 12.3.1. Company Overview
    • 12.3.2. Financial Performance
    • 12.3.3. Product Portfolio
    • 12.3.4. Strategic Initiatives
  • 12.4. Cipla Inc.
    • 12.4.1. Company Overview
    • 12.4.2. Financial Performance
    • 12.4.3. Product Portfolio
    • 12.4.4. Strategic Initiatives
  • 12.5. Genentech, Inc.
    • 12.5.1. Company Overview
    • 12.5.2. Financial Performance
    • 12.5.3. Product Portfolio
    • 12.5.4. Strategic Initiatives
  • 12.6. Gilead Sciences, Inc.
    • 12.6.1. Company Overview
    • 12.6.2. Financial Performance
    • 12.6.3. Product Portfolio
    • 12.6.4. Strategic Initiatives
  • 12.7. Merck & Co., Inc.
    • 12.7.1. Company Overview
    • 12.7.2. Financial Performance
    • 12.7.3. Product Portfolio
    • 12.7.4. Strategic Initiatives
  • 12.8. ViiV Healthcare
    • 12.8.1. Company Overview
    • 12.8.2. Financial Performance
    • 12.8.3. Product Portfolio
    • 12.8.4. Strategic Initiatives
  • 12.9. Others
    • 12.9.1. Company Overview
    • 12.9.2. Financial Performance
    • 12.9.3. Product Portfolio
    • 12.9.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 2 Global Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 3 North America Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 4 North America Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 5 U.S. Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 6 U.S. Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 7 Canada Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 8 Canada Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 9 Rest of North America Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 10 Rest of North America Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 11 UK and European Union Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 12 UK and European Union Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 13 UK Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 14 UK Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 15 Germany Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 16 Germany Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 17 Spain Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 18 Spain Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 19 Italy Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 20 Italy Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 21 France Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 22 France Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 23 Rest of Europe Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 24 Rest of Europe Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 25 Asia Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 26 Asia Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 27 China Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 28 China Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 29 Japan Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 30 Japan Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 31 India Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 32 India Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 33 Australia Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 34 Australia Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 35 South Korea Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 36 South Korea Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 37 Latin America Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 38 Latin America Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 39 Brazil Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 40 Brazil Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 41 Mexico Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 42 Mexico Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 43 Rest of Latin America Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 44 Rest of Latin America Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 45 Middle East and Africa Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 46 Middle East and Africa Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 47 GCC Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 48 GCC Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 49 Africa Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 50 Africa Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)
  • TABLE 51 Rest of Middle East and Africa Human Immunodeficiency Virus Therapeutics Market By Drug Type, 2023-2033, USD (Million)
  • TABLE 52 Rest of Middle East and Africa Human Immunodeficiency Virus Therapeutics Market By Drug Class, 2023-2033, USD (Million)

List of Figures

  • FIG. 1 Global Human Immunodeficiency Virus Therapeutics Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Human Immunodeficiency Virus Therapeutics Market: Quality Assurance
  • FIG. 5 Global Human Immunodeficiency Virus Therapeutics Market, By Drug Type, 2024
  • FIG. 6 Global Human Immunodeficiency Virus Therapeutics Market, By Drug Class, 2024
  • FIG. 7 Global Human Immunodeficiency Virus Therapeutics Market, By Geography, 2024
  • FIG. 8 Market Geographical Opportunity Matrix - Global Human Immunodeficiency Virus Therapeutics Market, 2024
  • FIG. 9Market Positioning of Key Human Immunodeficiency Virus Therapeutics Market Players, 2024
  • FIG. 10 Global Human Immunodeficiency Virus Therapeutics Market, By Drug Type, 2024 Vs 2033, %
  • FIG. 11 Global Human Immunodeficiency Virus Therapeutics Market, By Drug Class, 2024 Vs 2033, %